On BH3 Mimetics and Ca2+ Signaling

被引:4
|
作者
Ferdek, Pawel E. [1 ]
Jakubowska, Monika A. [1 ]
机构
[1] Cardiff Univ, Cardiff Sch Biosci, Med Res Council Grp, Cardiff CF10 3AX, S Glam, Wales
基金
英国医学研究理事会;
关键词
Bcl-2; BH3; mimetics; calcium; cell signaling; clinical trials; protein-protein interaction; SELECTIVE BCL-2 INHIBITOR; ENDOPLASMIC-RETICULUM; CELL-DEATH; OUTER-MEMBRANE; APOPTOSIS; DOMAIN; PROTEINS; MODULATION; DISCOVERY; CHANNELS;
D O I
10.1002/ddr.21405
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
BH3 mimetics are anticancer agents that reproduce the spatial arrangement of the BH3 domain of Bcl-2 family proteins. Just like the BH3-only proteins, these compounds bind to the hydrophobic cleft of the pro-survival Bcl-2 members such as Bcl-2 or Bcl-xL, and disrupt their heterodimerization with pro-apoptotic Bax or Bak, sensitizing cells to chemotherapy. In recent years, it has become clear that Bcl-2 family proteins are engaged in regulation of intracellular Ca2+ homeostasis, including Ca2+ release from the intracellular stores as well as Ca2+ fluxes across the plasma membrane. Given that BH3 mimetics shift the balance between the prosurvival and proapoptotic Bcl-2 members, they might indirectly exert effects on intracellular Ca2+ signals. Indeed, it has been reported that some BH3 mimetics release Ca2+ from the intracellular stores causing Ca2+ overload in the cytosol. Therefore, the effects of any new BH3 mimetics on cellular Ca2+ homeostasis should be tested before these compounds progress to clinical trials. Drug Dev Res 78 : 313-318, 2017. (c) 2017 Wiley Periodicals, Inc.
引用
收藏
页码:313 / 318
页数:6
相关论文
共 50 条
  • [1] BH3 Mimetics for the Treatment of Prostate Cancer
    Wolf, Philipp
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [2] The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca2+ signaling
    Vervloessem, Tamara
    Ivanova, Hristina
    Luyten, Tomas
    Parys, Jan B.
    Bultynck, Geert
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2017, 1864 (06): : 968 - 976
  • [3] BH3 mimetics as a strategy to complement anticancer therapies
    Hartman, Mariusz L.
    Czyz, Malgorzata
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2012, 66 : 67 - 77
  • [4] BH3 Mimetics: Status of the Field and New Developments
    Billard, Christian
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) : 1691 - 1700
  • [5] IFN-y Signaling Sensitizes Melanoma Cells to BH3 Mimetics
    Ming, Zizhen
    Lim, Su Yin
    Stewart, Ashleigh
    Pedersen, Bernadette
    Shklovskaya, Elena
    Menzies, Alexander M.
    Carlino, Matteo S.
    Kefford, Richard F.
    Lee, Jenny H.
    Scolyer, Richard A.
    V. Long, Georgina
    Rizos, Helen
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (07) : 1246 - +
  • [6] BH3 Mimetics in Hematologic Malignancies
    Klener, Pavel
    Sovilj, Dana
    Renesova, Nicol
    Andera, Ladislav
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [7] Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
    Hartman, Mariusz L.
    Czyz, Malgorzata
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (08) : 966 - 981
  • [8] BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
    Ramesh, Prashanthi
    Medema, Jan Paul
    APOPTOSIS, 2020, 25 (5-6) : 305 - 320
  • [9] Overview of BH3 mimetics in ovarian cancer
    Del Bufalo, Donatella
    Damia, Giovanna
    CANCER TREATMENT REVIEWS, 2024, 129
  • [10] It's time to die: BH3 mimetics in solid tumors
    Kehr, Sarah
    Vogler, Meike
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2021, 1868 (05):